Novartis India Ltd
- Market Cap ₹ 2,074 Cr.
- Current Price ₹ 840
- High / Low ₹ 1,248 / 790
- Stock P/E 24.0
- Book Value ₹ 295
- Dividend Yield 2.97 %
- ROCE 15.7 %
- ROE 10.9 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 2.86 times its book value
- The company has delivered a poor sales growth of -7.35% over past five years.
- Company has a low return on equity of 10.4% over last 3 years.
- Earnings include an other income of Rs.41.8 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE SmallCap BSE Healthcare BSE Allcap
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
901 | 859 | 870 | 690 | 656 | 564 | 491 | 438 | 381 | 400 | 379 | 335 | 354 | |
810 | 861 | 874 | 656 | 631 | 570 | 478 | 426 | 355 | 373 | 314 | 270 | 275 | |
Operating Profit | 90 | -1 | -4 | 34 | 25 | -6 | 12 | 12 | 27 | 27 | 65 | 65 | 79 |
OPM % | 10% | -0% | -0% | 5% | 4% | -1% | 2% | 3% | 7% | 7% | 17% | 19% | 22% |
83 | 95 | 101 | 207 | 71 | 172 | 78 | 36 | 33 | -17 | 58 | 62 | 42 | |
Interest | 0 | 0 | 0 | 0 | 1 | 6 | 2 | 6 | 8 | 5 | 2 | 1 | 1 |
Depreciation | 4 | 4 | 4 | 3 | 4 | 3 | 3 | 13 | 12 | 10 | 6 | 3 | 2 |
Profit before tax | 169 | 90 | 93 | 237 | 92 | 158 | 86 | 29 | 40 | -4 | 115 | 123 | 118 |
Tax % | 29% | -10% | 15% | 16% | 38% | 50% | 40% | 65% | 48% | -3% | 10% | 31% | |
120 | 99 | 79 | 198 | 57 | 78 | 52 | 10 | 21 | -4 | 103 | 85 | 86 | |
EPS in Rs | 37.46 | 30.83 | 24.75 | 62.04 | 20.33 | 31.74 | 20.97 | 4.08 | 8.46 | -1.51 | 41.86 | 34.50 | 34.95 |
Dividend Payout % | 27% | 32% | 40% | 16% | 49% | 32% | 48% | 245% | 118% | -663% | 113% | 72% |
Compounded Sales Growth | |
---|---|
10 Years: | -9% |
5 Years: | -7% |
3 Years: | -4% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | -2% |
5 Years: | 10% |
3 Years: | 59% |
TTM: | -10% |
Stock Price CAGR | |
---|---|
10 Years: | 3% |
5 Years: | 7% |
3 Years: | 10% |
1 Year: | -15% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 7% |
3 Years: | 10% |
Last Year: | 11% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16 | 16 | 16 | 16 | 14 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
Reserves | 884 | 945 | 986 | 1,178 | 906 | 721 | 747 | 708 | 699 | 679 | 763 | 732 | 717 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 68 | 62 | 24 | 22 | 7 | 6 | |
241 | 241 | 244 | 239 | 230 | 377 | 223 | 289 | 229 | 242 | 186 | 173 | 156 | |
Total Liabilities | 1,141 | 1,202 | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 891 |
10 | 8 | 8 | 6 | 6 | 5 | 15 | 76 | 64 | 24 | 19 | 7 | 6 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
1,131 | 1,194 | 1,238 | 1,426 | 1,144 | 1,106 | 967 | 1,001 | 938 | 934 | 964 | 918 | 885 | |
Total Assets | 1,141 | 1,202 | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 891 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | -5 | -60 | 57 | -41 | 161 | -194 | -23 | -69 | 39 | 45 | 113 | |
-16 | 22 | 719 | -630 | 424 | 69 | 274 | 56 | 95 | 87 | -153 | 33 | |
-37 | -38 | -38 | -39 | -332 | -268 | -30 | -41 | -37 | -36 | -30 | -121 | |
Net Cash Flow | -46 | -20 | 622 | -612 | 51 | -38 | 50 | -9 | -11 | 90 | -139 | 26 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 33 | 33 | 35 | 27 | 23 | 28 | 34 | 31 | 37 | 41 | 35 | 45 |
Inventory Days | 108 | 96 | 103 | 92 | 104 | 84 | 111 | 117 | 119 | 117 | 99 | 82 |
Days Payable | 117 | 100 | 98 | 89 | 87 | 158 | 168 | 145 | 137 | 148 | 108 | 112 |
Cash Conversion Cycle | 24 | 29 | 40 | 30 | 40 | -45 | -23 | 3 | 19 | 10 | 26 | 15 |
Working Capital Days | 317 | 353 | 6 | -35 | -14 | -99 | 7 | 9 | 75 | -18 | -33 | -57 |
ROCE % | 20% | 10% | 9% | 22% | 9% | 17% | 12% | 5% | 6% | 6% | 15% | 16% |
Documents
Announcements
-
This Is To Inform That The Company Has Received Order From Assistant Commissioner Of CGST And Central Excise And Disclosure Is Given Pursuant To Regulation 30 Read With Clause 20 Of Para A Of Schedule III
20 Feb - Novartis received service tax demand and penalty order.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 Jan - In relation to the publication of financial results for the Quarter ended as on December 31, 2024, approved by the Board in their meeting held …
-
Filing Of Unaudited Financial Results And Limited Review Report For The Quarter And Nine Months Ended December 31, 2024
28 Jan - Board approved unaudited financial results for Q3 2024.
-
Board Meeting Outcome for Filing Of Outcome Of The Meeting Of Board Of Novartis India Limited Held On January 28, 2024
28 Jan - Board approved unaudited financial results for Q3 2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Jan - Compliance certificate issued by MUFG Intime India Private limited(formerly known as Link Intime India Private Limited) dated January 07, 2025 under regulation 74(5) of the …
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business
The company is primarily engaged in the pharmaceutical business in the area of pain management, organ transplantation, neuroscience, etc. [1]